FDA Approves LIFYORLI (RELACORILANT) — New Treatment Available

WHY IT MATTERS

This approval marks the availability of a new treatment option for patients with Cushing's syndrome, a serious hormonal disorder where the body produces too much cortisol.

The FDA has approved a new medication called LIFYORLI (relacorilant) made by Corcept Therapeutics. This drug was officially approved on March 25, 2026. LIFYORLI is a new treatment option that is now available for patients who need it.

Drug: LIFYORLI Generic name: RELACORILANT Sponsor: CORCEPT THERAP Application: NDA220641 (ORIG) FDA approval date: 2026-03-25 Source: FDA Drugs@FDA database

YOU CAN ACT ON THIS

If you have Cushing's syndrome, talk to your doctor right away about whether LIFYORLI might be appropriate for your treatment plan.